{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/eczema-atopic/how-up-to-date-is-this-topic/update/","result":{"pageContext":{"chapter":{"id":"6d4019a1-b2bb-54e9-895a-a2edc7b87429","slug":"update","fullItemName":"Update","depth":2,"htmlHeader":"<!-- begin field c31069c2-7ecc-4b08-aa37-dbc0c060b9fd --><h2>Update</h2><!-- end field c31069c2-7ecc-4b08-aa37-dbc0c060b9fd -->","summary":null,"htmlStringContent":"<!-- begin item 62ed2694-72af-495e-9d69-6c9ca7bf263e --><!-- end item 62ed2694-72af-495e-9d69-6c9ca7bf263e -->","topic":{"id":"63a4e43b-49fe-563e-ac98-e9b0859c592c","topicId":"68307f26-e94a-48b4-9595-fadcb2fdee8a","topicName":"Eczema - atopic","slug":"eczema-atopic","lastRevised":"Last revised in January 2021","chapters":[{"id":"168b58b7-fdd4-50a2-b9ec-27d907398222","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8bb5c02b-0104-5f27-98ba-1b53ded774ba","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"98e1b8e0-503c-57ac-9ef2-caacc212e152","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d176eafc-9dcd-5f10-84a7-1d302a858223","slug":"changes","fullItemName":"Changes"},{"id":"6d4019a1-b2bb-54e9-895a-a2edc7b87429","slug":"update","fullItemName":"Update"}]},{"id":"9c4faee5-cf0b-515b-bc4a-a31602a94782","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"538ef47b-cfe7-5fca-beb8-19aa8e5bf9c1","slug":"goals","fullItemName":"Goals"},{"id":"a0383042-27f4-54a3-a484-e3a5a53f6625","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2c77a3c3-9932-5d7d-91b5-418e832f5312","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8baad0b5-8401-5866-829c-d480e381e783","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a521d8b1-827a-5781-ad45-f3791b4e1bd1","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8cf8749d-acfe-5549-ab78-d5cf32ea5fbf","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a7eb5aa7-360a-51dc-8e4c-daad28913df0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5a643f13-59c4-52ad-b851-dc4e8a73f354","slug":"definition","fullItemName":"Definition"},{"id":"ebbfabd2-e0e3-5987-aa33-c3fa2ba187da","slug":"causes","fullItemName":"Causes"},{"id":"e7a40326-66ce-59e3-bdcb-86b1b0b611ea","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9944d177-a960-52fd-8b8c-6d34afadddcb","slug":"complications","fullItemName":"Complications"},{"id":"01750b87-b8f0-5ec7-bda0-23ae3f563218","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"9692db09-38c6-5f1b-bc48-0e6606729c0c","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4ff05ba7-7a47-5830-a6d0-a3c723344964","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"b23630ce-69bb-56e8-9fae-e120331f815f","slug":"identifying-trigger-factors","fullItemName":"Identifying trigger factors"},{"id":"9cf9065e-b2c1-545d-a347-325c756ba267","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"084c2672-a546-5c1a-925f-c2b2579ea662","fullItemName":"Management","slug":"management","subChapters":[{"id":"d5478272-79bf-561d-86b2-264a10149cc9","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"0cccd619-b2de-56ab-aa4b-8335f760ada1","slug":"mild-eczema","fullItemName":"Scenario: Mild eczema"},{"id":"fd373e1c-c93c-5467-8984-3ffb57f4db96","slug":"moderate-eczema","fullItemName":"Scenario: Moderate eczema"},{"id":"60c5ed4a-3cf7-5f16-a959-9ebb082384a8","slug":"severe-eczema","fullItemName":"Scenario: Severe eczema"},{"id":"b127c625-6749-5a79-839f-88edee29b634","slug":"infected-eczema","fullItemName":"Scenario: Infected eczema"},{"id":"be3c1aab-3810-578d-a12d-7fa8a3bda3af","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"7a62824e-ab17-5ec8-b4eb-832ae0ea1ed2","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a6a60e24-add6-5b81-96c6-7556a07ce5ef","slug":"stepped-approach-to-treatment","fullItemName":"Stepped approach to treatment"},{"id":"32834cc1-317c-5325-a3c6-54b2bfa53088","slug":"emollients","fullItemName":"Emollients"},{"id":"93edf0ec-6483-5c88-a432-bb01d2b3b606","slug":"topical-corticosteroids","fullItemName":"Topical corticosteroids"},{"id":"33241bf6-534a-5809-8c00-641507b16a6b","slug":"oral-antihistamines","fullItemName":"Oral antihistamines"},{"id":"f30bf02b-a3bb-581a-bc1f-853575c7f434","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"6432a48a-76f3-534e-a4c1-8ec000fe6d58","slug":"oral-antibiotics","fullItemName":"Oral antibiotics"},{"id":"24b6d226-2567-5496-8557-dbfabde4e855","slug":"topical-antibiotics-antiseptics","fullItemName":"Topical antibiotics and antiseptics"}]},{"id":"a24fe8c8-994b-5b5d-a725-12ab08a2b0e6","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"aaad8885-ddf1-52ea-9dbb-520435cbe52b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2a17d479-605d-53c6-aac4-d2dee258e56e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"134abf73-7ae8-51e1-9f52-342c5379bcb0","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5fa037f5-1815-5c07-ad67-d491a2c34652","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4a76468f-46d6-51a1-9527-915b5596d2ad","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"15077c82-8b21-52ca-88cb-b5b956cd2ae6","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"cc9ef2ce-7217-5486-b5fe-23241bc45da4","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"98e1b8e0-503c-57ac-9ef2-caacc212e152","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"672602b9-34d2-5986-a246-feef78735e89","slug":"new-evidence","fullItemName":"New evidence","depth":3,"htmlHeader":"<!-- begin field cf7b0f1b-6d8e-4ada-8650-79204eba3347 --><h3>New evidence</h3><!-- end field cf7b0f1b-6d8e-4ada-8650-79204eba3347 -->","summary":null,"htmlStringContent":"<!-- begin item 1b4cfaf8-e45c-4e5a-8585-b14ebbf7d8ca --><!-- begin field 708c1559-a812-4c2a-826a-acdec928f70a --><h3>Evidence-based guidelines</h3><!-- end field 708c1559-a812-4c2a-826a-acdec928f70a --><!-- begin field f77212a9-088f-4948-9732-215ce92f9ef0 --><ul><li>Langan, S.M., Irvine, A.D., Weidinger, S. (2020) <em>Atopic dermatitis</em>. Lancet. <a href=\"https://www.thelancet.com/\" data-hyperlink-id=\"9efb97b0-e4fb-47e1-9ede-ac1000b4544d\">www.thelancet.com</a> [<a href=\"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31286-1/fulltext\" data-hyperlink-id=\"394aa942-2ca1-4b7b-9194-ac1000b45757\">Abstract</a>]</li></ul><!-- end field f77212a9-088f-4948-9732-215ce92f9ef0 --><!-- begin field 337f6f51-9a7b-4a12-9277-1f72fb223333 --><h3>HTAs (Health Technology Assessments)</h3><!-- end field 337f6f51-9a7b-4a12-9277-1f72fb223333 --><!-- begin field 9fd3ccdc-d8dc-4b87-a06b-985cba8c532b --><p>No new HTAs published since 1 February 2017.</p><!-- end field 9fd3ccdc-d8dc-4b87-a06b-985cba8c532b --><!-- begin field bacd7dbb-b064-408a-bc8a-8f72d3063042 --><h3>Economic appraisals</h3><!-- end field bacd7dbb-b064-408a-bc8a-8f72d3063042 --><!-- begin field 60559608-19a4-4854-b349-b415175726cc --><p>No new economic appraisals relevant to England since 1 February 2017.</p><!-- end field 60559608-19a4-4854-b349-b415175726cc --><!-- begin field 8e2075ce-6883-4999-b34e-c2c80bea78e7 --><h3>Systematic reviews and meta-analyses</h3><!-- end field 8e2075ce-6883-4999-b34e-c2c80bea78e7 --><!-- begin field fd7afe5f-1ef8-4024-ad21-6b4f58ea5215 --><ul><li>BMJ (2018) <em>Severe and predominantly active atopic eczema in adulthood and </em><em>long term</em><em> risk of cardiovascular disease: population based cohort study. </em>The British Medical Journal. <a href=\"https://www.bmj.com/\" data-hyperlink-id=\"c3b1102d-4e65-4266-ae16-a8f70152b183\">www.bmj.com</a> [<a href=\"https://www.bmj.com/content/361/bmj.k1786\" data-hyperlink-id=\"7c69eaf8-ec63-4379-8615-a8f70152b18c\">Free Full-text</a>]</li><li>Ramirez, F., Chen, S., Langan, S., et al. (2019) <em>Association of atopic dermatitis with sleep quality in children. </em>JAMA Pediatrics. <a href=\"https://jamanetwork.com/\" data-hyperlink-id=\"5c221c5f-5974-4ae9-bebf-aa1400f5c8ff\">www.jamanetwork.com</a> [<a href=\"https://jamanetwork.com/journals/jamapediatrics/fullarticle/2725861\" data-hyperlink-id=\"6be345db-d754-4383-8ff8-aa1400f5c9b0\">Free Full-text</a>]</li><li>Sawangjit, R., Dilokthornsakul, P., Lloyd-Lavery, A., et al. (2020) <em>Systematic treatments for eczema: a network meta-analysis. </em>Cochrane Library. <a href=\"https://www.cochranelibrary.com/\" data-hyperlink-id=\"233625af-27c1-4e10-9039-ac3d00be9bb9\">www.cochranelibrary.com</a> [<a href=\"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013206.pub2/full\" data-hyperlink-id=\"3c682fb1-21c9-468a-8931-ac3d00be9c90\">Free Full-text</a>]</li></ul><!-- end field fd7afe5f-1ef8-4024-ad21-6b4f58ea5215 --><!-- begin field 2fb1a0d5-1aa0-4c53-b1d0-0cde29b34bb3 --><h3>Primary evidence</h3><!-- end field 2fb1a0d5-1aa0-4c53-b1d0-0cde29b34bb3 --><!-- begin field 26d94a9f-73e5-4476-a9eb-39bcc92fca7a --><ul><li>NIHR Signal (2018) Adding emollients to the bath unlikely to help children with eczema. NIHR Signal. <a href=\"https://discover.dc.nihr.ac.uk/content/signal-000639/adrenaline-can-restart-the-heart-but-is-no-good-for-the-brain\" data-hyperlink-id=\"543e8cdd-132a-40f3-a143-a95700da55ac\">www.discover.dc.nihr.ac.uk</a> [<a href=\"https://discover.dc.nihr.ac.uk/content/signal-000629/adding-emollients-to-the-bath-unlikely-to-help-children-with-eczema\" data-hyperlink-id=\"35e3538f-db86-4d10-a736-a95700da55fc\">Free Full-text</a>]</li></ul><!-- end field 26d94a9f-73e5-4476-a9eb-39bcc92fca7a --><!-- end item 1b4cfaf8-e45c-4e5a-8585-b14ebbf7d8ca -->","subChapters":[]},{"id":"e0c56f60-6cf4-5d08-b0f6-5faf0799ccd0","slug":"new-policies","fullItemName":"New policies","depth":3,"htmlHeader":"<!-- begin field 1052496c-3f56-47a5-848e-0fcb2a218a65 --><h3>New policies</h3><!-- end field 1052496c-3f56-47a5-848e-0fcb2a218a65 -->","summary":null,"htmlStringContent":"<!-- begin item a3fe258d-cda8-47f7-9f8f-c5fbdc493a51 --><!-- begin field 9bffe7e4-e075-4ed1-a2e1-fba1b3b37251 --><p>No new national policies or guidelines since 1 February 2017.</p><!-- end field 9bffe7e4-e075-4ed1-a2e1-fba1b3b37251 --><!-- end item a3fe258d-cda8-47f7-9f8f-c5fbdc493a51 -->","subChapters":[]},{"id":"79e50c05-b01a-5331-89bb-6253063c45e5","slug":"new-safety-alerts","fullItemName":"New safety alerts","depth":3,"htmlHeader":"<!-- begin field 92393fdd-1fb6-4802-9d1e-ba399e58bbe1 --><h3>New safety alerts</h3><!-- end field 92393fdd-1fb6-4802-9d1e-ba399e58bbe1 -->","summary":null,"htmlStringContent":"<!-- begin item 584d8628-b209-44ed-8b80-fde3fcfe38eb --><!-- begin field 0f9c38b3-3d22-4cc1-89cc-127f58454f9b --><p>No new safety alerts since 1 February 2017.</p><!-- end field 0f9c38b3-3d22-4cc1-89cc-127f58454f9b --><!-- end item 584d8628-b209-44ed-8b80-fde3fcfe38eb -->","subChapters":[]},{"id":"61adb2f2-8caa-5e87-ae58-e7b5f2292962","slug":"changes-in-product-availability","fullItemName":"Changes in product availability","depth":3,"htmlHeader":"<!-- begin field 0a216735-26d3-4a4d-93a6-363b2f86f583 --><h3>Changes in product availability</h3><!-- end field 0a216735-26d3-4a4d-93a6-363b2f86f583 -->","summary":null,"htmlStringContent":"<!-- begin item ce22da43-c58e-4c89-a125-c82c0cc16b39 --><!-- begin field 1b6e78f1-7074-4029-9f31-dda5ad4fdef1 --><ul><li>Trimovate (clobetasone/nystatin/oxytetracycline), which was divested by the previous manufacturer in October 2017, has been relaunched as a licensed medicine by Ennogen Healthcare and is now available at an NHS list price of £12.45 for 30g. See more <a href=\"https://www.mims.co.uk/trimovate-available-prescribe-again/dermatology/article/1578190\" data-hyperlink-id=\"2a2d8705-108d-453c-8678-aa1400f4e78c\">here</a>.</li><li>Dupilumab is being made available to children 6 to 11 years of age with severe atopic dermatitis who are candidates for systemic therapy and where existing therapies are not advisable. See more <a href=\"https://www.gov.uk/government/publications/dupilumab-in-the-treatment-of-children-aged-6-to-11-years-of-age-with-severe-atopic-dermatitis-allergic-eczema\" data-hyperlink-id=\"528536ee-e147-484c-bc03-ac1e00bfe008\">here</a>.</li><li>Baricitinib is recommended for approval for the treatment of moderate-to-severe atopic dermatitis in adults. Barcitinib is currently approved in the EU to treat moderate-to-severe rheumatoid arthritis in adults who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. See more <a href=\"https://www.ema.europa.eu/en/medicines/human/summaries-opinion/olumiant\" data-hyperlink-id=\"4c86476c-cb73-4f69-ab1a-ac3d00bd2811\">here</a>.</li></ul><!-- end field 1b6e78f1-7074-4029-9f31-dda5ad4fdef1 --><!-- end item ce22da43-c58e-4c89-a125-c82c0cc16b39 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}